Outlook Business Initiative

Sakar Healthcare Inaugurates Research Laboratories

(R & D, F & D, ADL)- part of fully integrated anti-cancer API & Finished Dosage Formulation manufacturing Unit

Published 3 years ago on Oct 24, 2021 3 minutes Read
Sanjay Shah, Founder and Managing Director, Sakar Healthcare

Sakar Healthcare located at Ahmedabad, Gujarat, India has introduced the research driven comprehensive oncology R&D, ADL and F&D labs which are parts of API integrated oncology finished dosage manufacturing unit. The standalone facility is to get fully operational in phases to further scale-up commercial activities and shall include

Manufacturing units for formulations (Tab, cap, Liquid & lyophilized injections)

Manufacturing unit for API

The plant has been strategically designed to manufacture products with world-class standards using high-grade OEL level 4 equipments. The granulation-compression containment lines from GEA-Belgium, De-Deitrich Glass Line reactors & packing line of IMA- Italy, etc. are currently under installation; whereas Lyophiliser from Tofflon-China is under FAT, all these are to ensure world - class regulatory requirements.

The labs have been designed with updated set up incorporating modern technologies like Flow-chemistry by Vapourtech-UK, having capacity of 1ml to 10ml. Flow chemistry is a continuous method in which the chemical reaction happens in a tube reactor as the precursors are passingnthrough. This method has been used during past two decades mainly in the pharmaceutical industry which offers precise control of the four critical reaction parameters: stoichiometry, mixing, temperature and reaction time. The advantage soft his method over conventional batch reactions are the higher surface to volume ratio, easier heat and mass transfer resulting in more efficient reaction, and easier control and scale up. The introduction of continuous-flow chemistry (where operation is in steady state with a continuous reactant feed and product discharge, rather than dynamic batch) can favorably influence sustainability of manufacturing processes. Performing reactions in continuous flow can increase yields, optimize resources, minimize waste generation, and improve the safety of processes. This has not gone unnoticed by Sakar Healthcare in its drive to implement more sustainable and less wasteful processes and thus opted to include such technological advantage in the lab set up. The utilization of flow chemistry in the pharmaceutical industry is anticipated to witness the fastest growth in conducting reactions, continuous separations, and continuous crystallization. Flow chemistry delivers a significantly high yield while reducing the energy and solvent waste by over 90%. This has led to increased acceptance of the technology for numerous applications. Regulatory bodies including the U.S. Food and Drug Administration\ (FDA) and the European Commission support the use of flow chemistry for manufacturing Active Pharmaceutical Ingredients (APIs) and chemicals. Asia Pacific emerged as the fastest-growing market for flow chemistry, registering a CAGR of 11.4% from 2020 to 2028. Rising health awareness, leading to increasing demand for generic drugs, is expected to propel the utilization of flow chemistry processes to scale up the manufacturing of generic drugs. The inclusion of modern equipments including Flow-Chemistry and rich industry knowledge of technical teamleads have made the research units competent enough to grab two overseas project contracts for Sakar, the development operation has started. This is an encouraging milestone for the oncology research unit and for Sakar Healthcare as a whole.